FT : OpenAI trims valuation target to $1.25tn after pitching higher price AI lab

OpenAI trims valuation target to $1.25tn after pitching higher price
AI lab floated $1.4tn price tag earlier this month, according to documents seen by the FT

OpenAI has cut its valuation target for its latest funding round after facing resistance on a $1.4tn price tag from some investors, as it pushes to raise $30bn before going public next year.

The ChatGPT maker is in the final stages of a deal which is expected to value the company at $1.25tn, according to people with knowledge of the matter.

That would be a jump of almost 50 per cent from its current $852bn valuation, but is lower than the price pitched to investors earlier this month, according to people familiar with the matter.

The lower funding target comes as US tech stocks have sold off sharply, due to intensifying concerns about the sustainability of the debt-fuelled AI infrastructure boom.

Morgan Stanley and San Francisco-based tech fund Dragoneer had floated OpenAI to the bank’s private wealth clients at a pre-money valuation of $1.4tn, according to documents seen by the FT.

Multiple people with knowledge of the Morgan Stanley-led process said demand from clients was weaker than in the past. “There has been zero clamouring,” said one of the people. “All the prior times [OpenAI] have been on there’s been a frenzy. This time is a bit of a thud.”

Some investors were also suffering from fatigue, or “indigestion”, having invested heavily in prior rounds, said some of the people. OpenAI raised $40bn in March 2025 and a record-breaking $122bn in March this year. Arch-rival Anthropic has also raised close to $100bn this year.

Other investors told the FT they would rather wait and see how Anthropic prices in an initial public offering, expected later this year, before committing to its rival.

OpenAI is targeting raising $30bn as a “bridge” before its own public offering. That was likely to come in the first half of 2027, said a person close to the company, though no date has been fixed.

US investment group Coatue and funds from the United Arab Emirates were in discussion to lead the round, said one of the people with knowledge of the deal.

The deal also gives OpenAI right of first refusal on new computing power developed by its partners in the UAE, they added.

The company has given prospective investors until October 30 to commit to the deal, and may ultimately raise less than $30bn depending on investor interest.

OpenAI declined to comment. Coatue did not immediately respond to a request for comment. CNBC on Thursday reported that OpenAI was nearing a deal at $1.25tn.

Jimmy Chang, chief investment officer at the Rockefeller Global Family Office, which has exposure to OpenAI and Anthropic, said uncertainty around both of the companies’ IPOs was weighing on the broader US stock market.

“The market needs to see a successful IPO,” said Chang. “These companies need funding.”

>>> US After Hours Summary: RNG +14.1%, RHI +10.1%, ITG +4.5%, OMC +2.3%, NEM +1

After Hours Summary: RNG +14.1%, RHI +10.1%, ITG +4.5%, OMC +2.3%, NEM +1.9%, KN +1.9% higher on earnings; DECK -7.4%, FIX -5.8%, WDC -5.5%, KNSL -5.3%, BE -4.9%, KRC -4.9%, SSNC -4.8% lower on earnings

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings/guidance:RNG +14.1%, RHI +10.1%, ITG +4.5%, OMC +2.3%, NEM +1.9%, KN +1.9%

Companies trading higher in after hours in reaction to news:MSGS +3.1% (Expects to complete the MSG Rangers spinoff October 27 and rename itself MSG Knickerbockers.), VYLR +1.9% (Authorized a new $3 billion multi-year share repurchase program, effective immediately with no expiration date.), ADEA +1.5% (Renewed a multi-year media intellectual property license agreement with TCL.), HURN +1.4% (Will join the S&P SmallCap 600 before trading opens November 2, replacing Supernus Pharmaceuticals.), WPP +1.1% (Retains Coca-Cola’s global creative account and media business outside North America, Japan and South Korea after review.)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings/guidance:DECK -7.4%, FIX -5.8%, WDC -5.5%, KNSL -5.3%, BE -4.9%, KRC -4.9%, SSNC -4.8%, SLM -4.5%, MXL -3.6%, BYD -2.6%, VRSN -2.6%, BFH -2.0%, VLY -2.0%, SAM -1.8%, ENVA -1.3%, THRM -1.3%, PCG -1.1%, POOL -1.0%, COLB -1.0%

Companies trading lower in after hours in reaction to news: MACI -3.2% (Shareholders approved the Everli Global business combination, with closing expected after remaining conditions are met.)

The Information : The Closing of the ‘Defenders Window’ Is Nigh

The Closing of the ‘Defenders Window’ Is Nigh

At first, the X headlines this morning about the latest AI-powered cybersecurity incident seemed dire. But by the time I had a cup of coffee and began parsing all the cyber jargon, I was reassured that an apparent solution was on its way to plug a major new security hole that could make websites vulnerable to cyberintrusions. Since August, a coalition led by OpenAI has been working to address critical vulnerabilities in PHP, an open-source programming language that undergirds the web. But there was bad news, too: This type of long-simmering response to the latest AI-discovered vulnerabilities may not be viable for much longer.

For months, OpenAI has been harping on what it calls the “defender’s window”—the critical period of time when cybersecurity experts, armed with advanced AI models, can identify and patch vulnerabilities before attackers exploit them first. The issue is that the gap is rapidly narrowing between cybercapable models from leading U.S. frontier labs and Chinese open-source models, which lack the restrictions U.S. labs impose on their models’ capabilities. Anthropic said as much in a blog post from late September warning that Chinese lab Z.ai’s GLM-5.3 model only lags the U.S. frontier models by about four months.

The good news: The Trump administration has a shiny new organization created for moments just like these. It’s called the Super Intelligence Force, a name that may elicit eyerolls from some of our more jaded readers. Still, I have heard over and over that all the AI industry wants is coordination and clarity from the White House. That, presumably, is what the SI Force will offer, led by heavy hitters including National Intelligence Director Jay Clayton and senior Defense Department official Emil Michael.

An OpenAI spokesperson told me today that they had briefed several agencies, including the Cybersecurity and Infrastructure Security Agency, about the PHP vulnerability, as well as briefing Clayton and Michael late last week, representing the first “major engagement” between OpenAI and the SI Force. The spokesperson added that the SI Force provided a central point to coordinate their communication across the broader government. According to a White House official, the SI Force’s work involved helping to put pressure on the “relevant parties” to deploy a vulnerability patch.

While the SI Force’s coordination function may not seem terribly ambitious, at least it’s a start. It’s worth remembering that the White House essentially had to reorient its entire AI policy in April with the announcement of Mythos. The arrival of Chinese cybercapable open models could represent a Mythos 2.0 moment. I spoke with one former White House official who told me solutions from even a few months ago, like the July Gold Eagle clearinghouse that allows organizations and government agencies to share and fix software vulnerabilities, might already be outdated. It’s up to the SI Force to create a path forward. The next major internet bug likely won’t have the luxury of a two-month-long defender’s window.

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • CVBF -16.6%, HXL -12.1%, SNA -10.8%, SON -10.6%, TTMI -7.5%, LRCX -7.4%, GGG -7.2%, THRM -6.5%, KALU -6.3%, LAZ -6.2%, OII -5.9%, NOK -5.7%, ROL -5.2%, TSCO -5.0%, IBM -5.0%, ROP -4.9%, FEIM -4.7%, COCO -4.6%, IAG -4.2%, AAL -4.1%, GL -3.7%, TSLA -3.4%, PSO -3.1%, MEDP -2.9%, CBRE -2.9%, VC -2.8%, ORI -2.8%, META -2.8%, MOH -2.7%, SSB -2.6%, FAF -2.5%, IHG -2.4%, LVS -2.2%, PHM -2.1%, HBAN -2.1%, CATY -2.0%, LUV -1.2%, BCS -1.0%
Other news:
  • FPS -6.2% (Appointed Amy Ard CFO as Ryan Fiedler stepped down and transitioned to an external consulting role.)
  • RCUS -6.2% (Priced a 14.3 million-share public offering at $17.50 each, raising approximately $250 million in gross proceeds.)
  • DGX -2.8% (Disclosed unauthorized access to its Quanum LSM system that may have exposed patient records.)
  • VINP -2.7% (Agreed to acquire 100% of Austral Resseguradora, expecting immediate double-digit accretion to distributable EPS.)
  • SPCX -2.4% (CEO Elon Musk wants to merge SpaceX with Tesla before President Trump leaves office.)
  • NBIS -2.2% (Secured a $3.5 billion senior facility from Citi to fund global capacity expansion.)
  • AMZN -2.2% (Will make FTC settlement payments to millions of people.)
  • KSA -2.1% (Houthi militants attacked a Saudi Arabian airport, killing one person.)
  • TT -1.9% (Agreed to acquire heat-transfer products supplier Cancoil Thermal in a deal expected to close before year-end.)
  • KKR -1.8% (Agreed to acquire IEP Technologies and Newson Gale from HOERBIGER, with closing expected in first-quarter 2027.)
  • KBR -1.1% (Won contracts to support AGF Nitrogen's ammonia plant revamps in Germany and Austria.)
  • MAT -1.1% (Appoints EdgePoint partner Lee Matheson to its board under a cooperation agreement with the 18% shareholder.)
  • C -1.1% (Provided Nebius Group a $3.5 billion senior secured financing facility supporting its global capacity build-out.)
Analyst comments:
  • BROS -2.7% (Downgraded to Sector Perform from Outperform at RBC Capital, with a $46 price target.)
  • BLDR -2.7% (Downgraded to Market Perform from Outperform at William Blair.)
  • AEG -2.5% (Downgraded to Neutral from Overweight at JPMorgan.)
  • UGP -1.5% (Downgraded to Neutral from Overweight at JPMorgan.)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • RTO +7.4%, QS +6.8%, IIIN +6.2%, ALLE +5.9%, SEIC +5.3%, KNX +4.4%, LBRT +4.2%, POOL +4.1%, SPOT +4.0%, LMT +3.8%, DOW +3.0%, PG +2.8%, R +2.8%, CURB +2.5%, KMI +2.3%, CSX +2.1%, SLG +2.1%, FCFS +2.0%, RS +1.7%, NTST +1.5%, VLY +1.5%
Other news:
  • BHVN +34.0% (FDA accepted Biohaven's Vyglxia NDA resubmission for review and set a first-quarter 2027 decision goal.)
  • RAPP +3.8% (CFO purchased 5,500 shares at $26.10, totaling approximately $143,550.)
  • ATOM +3.3% (Signed a joint development agreement with IQE to develop MST-enabled RF GaN-on-silicon wafers.)
  • KRRO +2.3% (Reported KRRO-111 achieved over 95% mRNA editing and reduced pathogenic hepatic Z-AAT by up to 95% preclinically.)
  • USO +1.6% (U.S. and Israel are reportedly preparing post-election strikes on Iran, potentially targeting its energy infrastructure.)
  • MTDR +1.0% (Raised its quarterly dividend 17% to $0.4375 per share, beginning in the fourth quarter.)
  • QGEN +1.0% (Agreed to EQT Private Equity's €46.50-per-share all-cash takeover offer, valuing the company at approximately €10.8 billion.)
Analyst comments:
  • WHF +3.4% (Upgraded to Outperform from Market Perform at Raymond James with a $9 price target.)
  • PBLS +2.2% (Initiated with a Buy rating and $40 price target at H.C. Wainwright.)
  • IONS +1.9% (Upgraded to Outperform from Market Perform at BMO Capital with a $66 target.)
  • RNA +1.0% (Initiated with a Buy rating and $15 price target at Roth Capital.)

>>> Comcast beats by $0.08, reports revs in-line (22.08) Reports Q3 (Sep) earnin

Comcast beats by $0.08, reports revs in-line (22.08)
  • Reports Q3 (Sep) earnings of $1.07 per share, excluding non-recurring items, $0.08 better than the FactSet Consensus of $0.99; revenues fell 6.1% year/year to $29.3 bln vs the $29.22 bln FactSet Consensus.
  • Domestic wireless customer line net additions were 368,000 and 1.6 mln over the last 12 months. Total wireless lines increased to 10.6 mln, reaching nearly 18% penetration of domestic residential broadband customers and 7% of total addressable wireless lines in footprint.
  • "...In Content & Experiences, Peacock delivered its second consecutive profitable quarter, generating $261 million in Adjusted EBITDA on $1.8 billion in revenue, driven by strong growth in distribution, while Universal surpassed $5 billion at the global box office, led by the record-breaking success of The Odyssey, now Universal's highest-grossing film of all time. Despite near-term cyclical headwinds in Theme Parks, we remain confident in the business's long-term growth potential. We generated $4.2 billion in free cash flow and are making meaningful progress on the separation of NBCUniversal and Sky, which remains on track to create two independent companies with the financial strength and flexibility to pursue their respective growth strategies."

>>> Nebius Group N.V. secures $3.5 billion financing facility with Citi (C) (171

Nebius Group N.V. secures $3.5 billion financing facility with Citi (C) (171.57)
  • Co announced that it has entered into a $3.5 billion senior secured facility provided by Citi.
  • The facility provides access to capital at attractive rates to support Nebius's global capacity build-out, and advances the company's diversified and sequenced funding strategy.
  • It complements a funding base that includes customer prepayments and operating cash flows with other financing mechanisms.
  • This provides flexibility over the timing and structure of further external capital-raising as the company continues to execute on its global build-out plans.

>>> BioNTech advances phase 3 clinical trial of Pumitamig in combination with Gi

BioNTech advances phase 3 clinical trial of Pumitamig in combination with Gilead’s (GILD) TROP2-directed ADC sacituzumab govitecan in triple-negative breast cancer (91.29)
  • Co announced a clinical trial collaboration and supply agreement with Gilead Sciences (GILD) to evaluate pumitamig in combination with the TROP2-directed antibody-drug conjugate sacituzumab govitecan as first-line treatment for patients with locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer. Pumitamig is an investigational bispecific immunomodulator designed to cooperatively bind to PD-L1 and VEGF-A that is being jointly developed by BioNTech and Bristol Myers Squibb (BMY).
  • ROSETTA Breast-01 is a global, double-blinded Phase 3 clinical trial (NCT07173751) currently evaluating pumitamig in combination with chemotherapy versus chemotherapy in patients with locally advanced or metastatic PD-L1 low or negative TNBC (CPS < 10), initiated based on positive results from a global Phase 2 trial. In line with the evolving treatment landscape in this indication, BioNTech and BMS plan to adapt ROSETTA Breast-01 replacing chemotherapy with sacituzumab govitecan, pending regulatory authority approval, to ensure that patients are receiving the latest standard of care treatment.
  • Under the terms of the agreement, BioNTech will continue to sponsor and lead the ROSETTA Breast-01 trial. Gilead will supply sacituzumab govitecan for the combination trial.

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • SEIC +10.5%, AVEX +10.4%, QS +8.5%, LBRT +4.2%, SPOT +4.0%, CADL +3.9%, KNX +3.3%, ROST +3.2%, CSX +3.2%, EXC +2.6%, IONS +2.5%, SLG +2.1%, ETRA +2.0%, FCFS +2.0%, KMI +1.9%, BSM +1.8%, WHF +1.6%, NTST +1.5%, LMT +1.3%, HAL +1.2%, QGEN +1.2%, WLTH +1.2%, HRL +1.2%, RNA +1.0%
  • Gapping down:
    • CVBF -16.6%, SON -10.6%, HXL -10.1%, GGG -8.6%, LRCX -7.8%, THRM -7.5%, RCUS -7.3%, ROL -6.7%, TTMI -6.2%, NOK -6.2%, KALU -5.2%, IBM -4.6%, MOH -4.2%, CLSK -4.0%, TSLA -4.0%, IAG -3.6%, DDD -3.6%, OII -3.6%, FAF -3.6%, BROS -3.4%, HBAN -3.4%, GL -3.3%, UMC -3.2%, VRT -3.2%, FEIM -3.2%, SMCI -3.2%, PSO -3.2%, IHG -3.1%, LVS -2.8%, VINP -2.7%, TLN -2.5%, SSB -2.4%, VST -2.4%, SPCX -2.3%, HSBC -2.3%, MEDP -2.2%, CATY -2.0%, NVDA -2.0%, NRG -2.0%, PCG -2.0%, TT -1.9%, UAL -1.9%, CEG -1.8%, AEG -1.7%, GOOG -1.6%, BLDR -1.6%, MAT -1.5%, MS -1.5%, CTSH -1.5%, IVZ -1.5%